Keratinocyte Growth Factor (KGF)

Modality

Keratinocyte Growth Factor (KGF)

Keratinocyte growth factor (KGF), also known as palifermin or FGF-7, is part of the FGF family, and KGF binding to its receptor induces epithelial cell proliferation, differentiation, and migration. With a high level of receptor specificity, it performs important roles in maintaining tissue regeneration and mucosal barrier integrity.

Because of these unique properties, researchers developed human recombinant KGF (palifermin) to promote the growth of damaged epithelial tissues. The use of palifermin has been demonstrated to be effective in attenuating chemotherapy- and radiotherapy-induced oral mucositis (OM) and improving patients' quality of life. KGF-derived proteins have been used for a variety of purposes and in a wide range of diseases, such as wound healing, tissue repair, diabetes, bladder and lung injuries, and gastrointestinal mucositis.

Application of KGF

Palifermin (Kepivance)

As a recombinant truncated human KGF comprising 140 amino acids, palifermin (Kepivance) is the first active ingredient approved for the prevention of oral mucositis in haematopoietic stem cell transplant (HSCT) patients. In Palifermin, what has been removed includes the KGF-1 signalling peptide and the subsequent 23 amino acid residues, resulting in a 10-fold increase in the specific activity of rhKGF compared to isolated KGF from fibroblasts. It is produced in Escherichia coli (E. coli) by recombinant DNA technology and developed by Biovitrum who focuses on organ drugs.

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for KGF

Keratinocyte growth factor (KGF) Pipelines

Types	Name	Alternative Name	Expression System	Indication	Manufacturer	Stage
KGF-1, FGF-7	Palifermin	AMJ 9701, Kepivance	E. coli	Stomatitis	Swedish Orphan Biovitrum AB	Approval
KGF-1, FGF-7	Palifermin biosimilar	Pending update	Pending update	Mucositis	Chengdu Zhitian Biological Engineering	Phase II
KGF-1, FGF-7	Recombinant Human Keratinocyte Growth Factor	Pending update	Pending update	Pending	Jiangsu Aosaikang Pharmaceutical	Phase I
KGF-2	Recombinant human keratinocyte growth factor-2	Pending update	Pending update	Burn	Shanghai Newsummit Biopharma	Phase III
KGF-2	Recombinant human keratinocyte growth factor-2	Pending update	Pending update	Burn	Wuhan Optics Valley New Medicine Incubation Public Service Platform Co Ltd	Phase III
KGF-2	Recombinant human keratinocyte growth factor-2	Pending update	Pending update	Corneal injury, Corneal disease, Keratitis	Guangzhou Jida Gene Pharmacy Engineering Research Center Co Ltd \| Wenzhou Medical University	Phase I

All Categories

Keratinocyte Growth Factor (KGF)

Modality